Evaluation of the “CLARI-RES ASSAY” by real-time for the detection of clarithromycin -resistant Helicobacter pylori in the upper gastrointestinal biopsies

Introduction. Clarithromycin is recognized as the main drug of first-line therapy for eradication of Helicobacter pylori (Hp) (Maastricht III Consensus 2006) and in vitro evaluation of its effectiveness is considered crucial. it was noted that some point mutations in domain V of 23S rRNA Hp are asso...

Full description

Bibliographic Details
Main Authors: Giorgio Mucignat, Anna Maria Baragiotta, Giorgio Benedetti, Anna Lagatta, Marina Crovatto
Format: Article
Language:English
Published: PAGEPress Publications 2010-12-01
Series:Microbiologia Medica
Subjects:
Online Access:http://www.pagepressjournals.org/index.php/mm/article/view/2410
_version_ 1811286104562728960
author Giorgio Mucignat
Anna Maria Baragiotta
Giorgio Benedetti
Anna Lagatta
Marina Crovatto
author_facet Giorgio Mucignat
Anna Maria Baragiotta
Giorgio Benedetti
Anna Lagatta
Marina Crovatto
author_sort Giorgio Mucignat
collection DOAJ
description Introduction. Clarithromycin is recognized as the main drug of first-line therapy for eradication of Helicobacter pylori (Hp) (Maastricht III Consensus 2006) and in vitro evaluation of its effectiveness is considered crucial. it was noted that some point mutations in domain V of 23S rRNA Hp are associated with resistance to macrolides and then is given the possibility of a molecular diagnostic capable, inter alia, to overcome some of the problems associated with classical microbiological techniques.They have been recently commercialized kit employing molecular methods able to identify some of these mutations, which are considered most often. Having assessed by sequencing, the relative frequency of mutations detected in local office, we wanted to compare the potential benefits of molecular diagnostics in comparison to cytological testing in normal use, and assess the frequency of strains with mutations linked to resistance to clarithromycin in population Local. Methods. 59 patients presenting disorders of the upper gastrointestinal tract were subjected to gastroscopy, biopsies were taken on which it runs parallel with the direct cytology and molecular method. Cytology was performed according to traditional method.The extraction of nucleic acids was performed with QIAamp DNA Mini Kit (Qiagen).The kit “H. pylori ClariRes assay” (Ingenetix GmbH.Vienna) was used for the detection of mutations A2142C,A2142/3G by RealTime on LightCycler 2.0 instrument (Roche). Results. 91.5% of results are concordant with both methods (54/59). 41 are positive for the presence of Hp and 18 are negative. No sample test are positive direct and negative for nucleic acids, vice versa in 5 samples are found DNA of Hp while the direct examination was negative. Of the 41 patients positive for Molecular good 19 (46.3%) appear to be carriers of Hp with mutations linked to resistance Clarithromycin. Conclusions.The molecular method is used and proved sensitive and reliable in clinical practice and to solve technical problems in the crop and in the test of sensitivity on the one hand and the difficulties of interpretation of cytology on the other.The response times are noticeably shorter. Highlighted the frequency of strains resistant to clarithromycin makes it even more this kind to establish a proper antibiotic therapy.
first_indexed 2024-04-13T02:54:46Z
format Article
id doaj.art-26473b48a3ec4c83bc1621d94011711d
institution Directory Open Access Journal
issn 2280-6423
language English
last_indexed 2024-04-13T02:54:46Z
publishDate 2010-12-01
publisher PAGEPress Publications
record_format Article
series Microbiologia Medica
spelling doaj.art-26473b48a3ec4c83bc1621d94011711d2022-12-22T03:05:42ZengPAGEPress PublicationsMicrobiologia Medica2280-64232010-12-0125410.4081/mm.2010.24101665Evaluation of the “CLARI-RES ASSAY” by real-time for the detection of clarithromycin -resistant Helicobacter pylori in the upper gastrointestinal biopsiesGiorgio MucignatAnna Maria BaragiottaGiorgio BenedettiAnna LagattaMarina CrovattoIntroduction. Clarithromycin is recognized as the main drug of first-line therapy for eradication of Helicobacter pylori (Hp) (Maastricht III Consensus 2006) and in vitro evaluation of its effectiveness is considered crucial. it was noted that some point mutations in domain V of 23S rRNA Hp are associated with resistance to macrolides and then is given the possibility of a molecular diagnostic capable, inter alia, to overcome some of the problems associated with classical microbiological techniques.They have been recently commercialized kit employing molecular methods able to identify some of these mutations, which are considered most often. Having assessed by sequencing, the relative frequency of mutations detected in local office, we wanted to compare the potential benefits of molecular diagnostics in comparison to cytological testing in normal use, and assess the frequency of strains with mutations linked to resistance to clarithromycin in population Local. Methods. 59 patients presenting disorders of the upper gastrointestinal tract were subjected to gastroscopy, biopsies were taken on which it runs parallel with the direct cytology and molecular method. Cytology was performed according to traditional method.The extraction of nucleic acids was performed with QIAamp DNA Mini Kit (Qiagen).The kit “H. pylori ClariRes assay” (Ingenetix GmbH.Vienna) was used for the detection of mutations A2142C,A2142/3G by RealTime on LightCycler 2.0 instrument (Roche). Results. 91.5% of results are concordant with both methods (54/59). 41 are positive for the presence of Hp and 18 are negative. No sample test are positive direct and negative for nucleic acids, vice versa in 5 samples are found DNA of Hp while the direct examination was negative. Of the 41 patients positive for Molecular good 19 (46.3%) appear to be carriers of Hp with mutations linked to resistance Clarithromycin. Conclusions.The molecular method is used and proved sensitive and reliable in clinical practice and to solve technical problems in the crop and in the test of sensitivity on the one hand and the difficulties of interpretation of cytology on the other.The response times are noticeably shorter. Highlighted the frequency of strains resistant to clarithromycin makes it even more this kind to establish a proper antibiotic therapy.http://www.pagepressjournals.org/index.php/mm/article/view/2410H. pylori, Claritromicina, Mutazione
spellingShingle Giorgio Mucignat
Anna Maria Baragiotta
Giorgio Benedetti
Anna Lagatta
Marina Crovatto
Evaluation of the “CLARI-RES ASSAY” by real-time for the detection of clarithromycin -resistant Helicobacter pylori in the upper gastrointestinal biopsies
Microbiologia Medica
H. pylori, Claritromicina, Mutazione
title Evaluation of the “CLARI-RES ASSAY” by real-time for the detection of clarithromycin -resistant Helicobacter pylori in the upper gastrointestinal biopsies
title_full Evaluation of the “CLARI-RES ASSAY” by real-time for the detection of clarithromycin -resistant Helicobacter pylori in the upper gastrointestinal biopsies
title_fullStr Evaluation of the “CLARI-RES ASSAY” by real-time for the detection of clarithromycin -resistant Helicobacter pylori in the upper gastrointestinal biopsies
title_full_unstemmed Evaluation of the “CLARI-RES ASSAY” by real-time for the detection of clarithromycin -resistant Helicobacter pylori in the upper gastrointestinal biopsies
title_short Evaluation of the “CLARI-RES ASSAY” by real-time for the detection of clarithromycin -resistant Helicobacter pylori in the upper gastrointestinal biopsies
title_sort evaluation of the clari res assay by real time for the detection of clarithromycin resistant helicobacter pylori in the upper gastrointestinal biopsies
topic H. pylori, Claritromicina, Mutazione
url http://www.pagepressjournals.org/index.php/mm/article/view/2410
work_keys_str_mv AT giorgiomucignat evaluationoftheclariresassaybyrealtimeforthedetectionofclarithromycinresistanthelicobacterpyloriintheuppergastrointestinalbiopsies
AT annamariabaragiotta evaluationoftheclariresassaybyrealtimeforthedetectionofclarithromycinresistanthelicobacterpyloriintheuppergastrointestinalbiopsies
AT giorgiobenedetti evaluationoftheclariresassaybyrealtimeforthedetectionofclarithromycinresistanthelicobacterpyloriintheuppergastrointestinalbiopsies
AT annalagatta evaluationoftheclariresassaybyrealtimeforthedetectionofclarithromycinresistanthelicobacterpyloriintheuppergastrointestinalbiopsies
AT marinacrovatto evaluationoftheclariresassaybyrealtimeforthedetectionofclarithromycinresistanthelicobacterpyloriintheuppergastrointestinalbiopsies